Insight Advisors’s Disc Medicine IRON Stock Holding History

Insight Advisors’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,295	Closed	-$454K	–	326
2021 Q1	$454K	Buy	+1,295	New	+$578K	0.14%	178

Other funds holding IRON

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Insight Advisors's IRON Position: Q2 2021 in Review

Insight Advisors sold out of Disc Medicine (IRON) in Q2 2021, closing a stake of 1,295 shares — an estimated $454K sold.

Insight Advisors first reported a position in IRON in Q1 2021 and held it in 1 quarter. The position peaked at $454K in Q1 2021. 55 funds tracked by Wall St. Rank hold IRON as of Q2 2021.

Insight Advisors reported no remaining Disc Medicine position as of Q2 2021 after selling out during the quarter.
Insight Advisors sold 1,295 Disc Medicine shares in Q2 2021, an estimated $454K.
Insight Advisors first reported a position in Disc Medicine in Q1 2021 and held it in 1 quarter.
Insight Advisors's Disc Medicine position peaked at $454K in Q1 2021.
55 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2021.

Based on Insight Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.